Clinical Trials Sponsored by BioIncept LLC

Total 10773 results

Hadassah Medical Organization
BioIncept LLC

Unknown

Safety Study of Preimplantation Factor (PIF-1) to Treat Acute Steroid-Resistant Graft-Versus-Host Disease (GVHD) (PIF1GVHD)

Graft Vs Host Disease

Israel
BioIncept LLC
Merck KGaA, Darmstadt, Germany

Unknown

Correlation Between PIF Maternal Serum Levels and Pregnancy Outcome (PIFBlood1)

Pregnancy

United States, France, Greece
BioIncept LLC
Merck KGaA, Darmstadt, Germany

Unknown

Prognostic Value of PIF Detection in Embryo Culture Media Correlation With Pregnancy Outcome (PIF-SET1)

Pregnancy | Fertility

United States, France, Greece
Regionshospitalet Viborg, Skive
Ferring Pharmaceuticals; BioIncept LLC

Completed

The Role of Progesterone and PIF for Successful Implantation and On-going Pregnancy in Assisted Reproductive Technology

Infertility

Denmark
Christopher O'Brien, MD
BioIncept LLC

Completed

sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS

Autoimmune Hepatitis

United States
Nordsjaellands Hospital
Yale University; Rigshospitalet, Denmark; BioIncept LLC

Completed

Early Pregnancy Cohort and Preimplantation Factor (PEP-cohort)

Pregnancy | Biomarkers | Abortion, Habitual | Abortion, Spontaneous | Luteal Phase
Christopher O'Brien, MD
BioIncept LLC

Withdrawn

Phase 2 Dose Finding sPIF in Patients With High Panel Reactive Antibodies

Panel Reactive Antibodies
Christopher O'Brien, MD
BioIncept LLC

Withdrawn

Phase II AutoImmune Hepatitis

Hepatitis, Autoimmune
Biocept, Inc.
ICON plc

Terminated

A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide (FORESEE)

Breast Cancer | Non-Small Cell Lung Cancer | Leptomeningeal Disease | Leptomeningeal Metastasis | Leptomeningeal Neoplasms

United States
BioInvent International AB
Merck Sharp & Dohme LLC

Recruiting

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Advanced Malignancies

United Kingdom, Denmark, Hungary, Russian Federation
BioInvent International AB
Merck Sharp & Dohme LLC

Recruiting

BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

Hepatocellular Carcinoma | Non Small Cell Lung Cancer | Solid Tumors

Spain, Denmark, Poland, Sweden
BioInvent International AB
Merck Sharp & Dohme LLC

Recruiting

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)

Solid Tumor, Adult

United States, Sweden
Transgene
Merck Sharp & Dohme LLC; BioInvent International AB

Recruiting

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Melanoma | Soft Tissue Sarcoma | Non Small Cell Lung Cancer | Metastatic Cancer | Triple Negative Breast Cancer | Merkel Cell Carcinoma

France, Belgium
BioInvent International AB

Active, not recruiting

BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors (CONTRAST)

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | HER2-positive Metastatic Breast Cancer

Spain, United Kingdom, Germany
BioInvent International AB

Terminated

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

Multiple Myeloma

United States
BioInvent International AB

Completed

A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma

Multiple Myeloma

Denmark, Belgium, United States, Sweden
BioInvent International AB

Recruiting

A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma

Indolent B-Cell Non-Hodgkin Lymphoma

Spain, United States, Brazil, Sweden, Germany, Poland
BioInvent International AB

Terminated

A Phase II Study of BI-505 in Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

Sweden
ThromboGenics
BioInvent International AB

Completed

Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery

Prophylaxis of Venous Thromboembolic Events

Austria, Netherlands, Belgium, Bulgaria, Hungary, Latvia, Poland, Russian Federation, Ukraine
ThromboGenics
BioInvent International AB

Completed

Effects of LMWH in Healthy Subjects Treated With TB-402 and Effects of TB-402 in Healthy Subjects Treated With Warfarin

Healthy

Denmark
ThromboGenics
BioInvent International AB

Completed

Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402

Healthy

Denmark
BioInvent International AB
Oxurion

Completed

Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours

Solid Tumors

Denmark
ThromboGenics
BioInvent International AB

Completed

A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers

Healthy

Denmark
ThromboGenics
Covance; BioInvent International AB

Completed

Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery

Total Knee Replacement Surgery

Israel, Romania, Bulgaria, Latvia, Poland, Russian Federation, Ukraine
Genentech, Inc.
BioInvent International AB

Completed

A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)

Atherosclerosis

United States, Canada
BioInvent International AB
Genentech, Inc.

Completed

Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy Subjects

Healthy

United Kingdom
Cancer Research UK
BioInvent International AB; Bloodwise

Completed

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

B-cell Lymphoma | Waldenström Macroglobulinemia | Chronic Lymphocytic Leukaemia

United Kingdom
Arthritis Northwest PLLC
Epigenesys LLC

Unknown

Identification of Epigenetic Biomarkers for Early Detection of Rheumatic Disease

Arthritis, Rheumatoid

United States
Angle plc
MidLantic Urology, LLC

Terminated

Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System (CHARTER)

Prostate Cancer | Castration-resistant Prostate Cancer | Biochemically Recurrent Prostate Carcinoma | High Risk Prostate Carcinoma

United States
Synochi, LLC
LAC+USC Medical Center

Not yet recruiting

Prospective Placebo-controlled Study of Synochi Scar Spray

Burns Multiple
LLS PedAL Initiative, LLC
Kura Oncology

Not yet recruiting

Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

Relapsed/Refractory KMT2A-r Acute Leukemia | Relapsed/Refractory NUP98-r Acute Leukemia | Relapsed/Refractory NPM1-m Acute Leukemia
Derm Research, PLLC
WFH MEDICAL, LLC

Completed

Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel

Acne Vulgaris

United States
Verily Life Sciences LLC
The Emmes Company, LLC; Optos, PLC; Google LLC.; Nikon Corporation

Completed

ARDA Software for the Detection of mtmDR

Diabetic Retinopathy

United States
Columbia University
National Cancer Institute (NCI); Biocept, Inc.

Completed

Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer

Breast Cancer | Leptomeningeal Metastasis

United States
MedRegen LLC
Johns Hopkins University; ICON plc

Recruiting

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

COVID-19 | ARDS, Human | Regeneration | Stem Cells

United States
IVFarma LLC
BridgePharm LLC; GlobalPharma LLC

Completed

Study to Compare Efficacy and Safety of Primapur and Gonal-f in Women for Assisted Reproductive Treatment

Infertility, Female

Russian Federation
Redx Pharma Plc
Merck Sharp & Dohme LLC

Completed

A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (KEYNOTE-E86)

Advanced Solid Tumours

United Kingdom, Australia
4D pharma plc
Merck Sharp & Dohme LLC

Terminated

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Melanoma | Renal Cell Carcinoma | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Oncology

United States
Pharmtechnology LLC
ClinPharmInvest, LLC

Not yet recruiting

Bioequivalence Study of Two Formulations of Sildenafil Tablet 100 mg in Healthy Male Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
IVFarma LLC
NADIM LLC

Completed

The Safety and Pharmacokinetics of Primapur and Gonal-f

Pharmacokinetics | Absorption | Area Under Curve

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Montelukast, 5 mg Chewable Tablets (Pharmtechnology LLC, Belarus), and Singulair®, 5 mg Chewable Tablets (Merck Sharp & Dohme B.V., the Netherlands), in Healthy Volunteers Under Fasting Conditions

Healthy Adults

Russian Federation
Immunitor LLC
Ekomed LLC

Unknown

Open Label Immunotherapy of Endometriosis

Endometriosis

Mongolia
Pharmtechnology LLC
ClinPharmInvest, LLC

Not yet recruiting

Bioequivalence Study of Two Formulations of Etoricoxib Tablets 120 mg in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Not yet recruiting

Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Two Formulations of Atorvastatin Film-coated Tablets 40 mg in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Two Formulations of Clopidogrel Film-coated Tablets 75 mg in Healthy Male Subjects Under Fasting Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (Pharmtechnology LLC, Belarus), and Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
Monsoon Design Studio LLC
Healthark Wellness Solutions LLP

Completed

Study of Evoked Emotional Responses

Emotion, Expressed

India
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Two Formulations of Torasemide Tablet 10 mg in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation

Clinical Trials Sponsored by BioIncept LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations